Company Description
ZeroStack Corp., through its subsidiary, Phatebo GmbH, engages in the pharmaceutical distribution business in Germany.
It operates through Commercial & Wholesale and Digital Assets segments. The company distributes a range of pharmaceutical goods and medical products to treat various health indications, including drugs related to cancer therapies, attention-deficit/hyperactivity disorder, multiple sclerosis, and anti-depressants.
It also operates as a decentralized AI treasury company that invests in the future of AI infrastructure through strategic ownership of 0G tokens.
In addition, the company invests in early-stage companies. The company was formerly known as Flora Growth Corp. and changed its name to ZeroStack Corp. in January 2026.
ZeroStack Corp. was incorporated in 2019 and is based in Toronto, Canada.
| Country | Canada |
| Founded | 2019 |
| IPO Date | May 11, 2021 |
| Industry | Asset Management |
| Sector | Financials |
| Employees | 75 |
| CEO | Daniel Reis-Faria |
Contact Details
Address: 40 King Street W, Suite 2400 Toronto, ON M5H 3Y2 Canada | |
| Phone | 954-842-4989 |
| Website | zerostack.ai |
Stock Details
| Ticker Symbol | ZSTK |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1790169 |
| CUSIP Number | 98956L101 |
| ISIN Number | CA98956L1013 |
| SIC Code | 5122 |
Key Executives
| Name | Position |
|---|---|
| Daniel Reis-Faria | Chief Executive Officer and Director |
| Michael Heinrich | Executive Chairman |
| Dany Vaiman | Chief Financial Officer |
| Dr. Manfred Ziegler | Managing Director |
| Patrick Moloney | Head of Product Development |
| Aaron Atin | Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 27, 2026 | 10-K | Annual Report |
| Jan 29, 2026 | 8-K | Current Report |
| Jan 27, 2026 | 424B5 | Filing |
| Jan 27, 2026 | FWP | Free Writing Prospectus |
| Jan 27, 2026 | 424B3 | Prospectus |
| Jan 26, 2026 | EFFECT | Notice of Effectiveness |
| Jan 8, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Jan 6, 2026 | 8-K | Current Report |
| Dec 31, 2025 | 8-K | Current Report |
| Dec 23, 2025 | 8-K | Current Report |